Legacy Wealth Asset Management LLC Buys 2,061 Shares of Amgen Inc. $AMGN

Legacy Wealth Asset Management LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 79.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,657 shares of the medical research company’s stock after purchasing an additional 2,061 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Amgen were worth $1,963,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Wellington Altus USA Inc. boosted its stake in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares in the last quarter. Tower View Wealth Management LLC raised its stake in shares of Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Amgen in the 2nd quarter worth $36,000. Evergreen Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at $37,000. Finally, Steph & Co. acquired a new stake in shares of Amgen in the third quarter valued at $42,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Down 1.4%

Shares of Amgen stock opened at $407.44 on Friday. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03. The firm has a market capitalization of $220.27 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 2.98 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock’s fifty day moving average is $412.35 and its 200-day moving average is $371.88.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Analyst Ratings Changes

A number of research firms recently issued reports on AMGN. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Piper Sandler upped their price target on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Oppenheimer restated an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. Cantor Fitzgerald raised their price objective on shares of Amgen from $400.00 to $440.00 and gave the company a “neutral” rating in a research report on Monday. Finally, Morgan Stanley lowered their price objective on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $388.29.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen is advancing a Phase 3 head-to-head trial of its monthly diabetes treatment, MariTide, against semaglutide-based therapy. A successful study could strengthen Amgen’s position in the highly competitive GLP-1 and obesity-treatment markets and provide a significant future growth opportunity. Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
• Positive Sentiment: Amgen’s recently announced Sjögren’s syndrome trial results appear to have supported investor sentiment, contributing to gains in the prior session. Further details on efficacy and regulatory plans will determine the longer-term impact. Amgen Announces Sjögren’s Trial Results
• Neutral Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing for AI-driven genetic testing. The investment may give Amgen access to molecular data useful for precision-medicine research, but it is unlikely to materially affect near-term earnings. Amgen Backs $30 Million Series A Round
• Neutral Sentiment: AMGN advanced about 2.6% in the prior session while the broader market declined, suggesting recent relative strength; however, this move may also have increased the potential for profit-taking. Amgen Advances While Market Declines
• Negative Sentiment: Morgan Stanley cut its price target to $359 from $362 and maintained an Equal Weight rating. Truist raised its target to $380 but kept a Hold rating. Both targets imply downside from Amgen’s recent price, reinforcing valuation concerns. Morgan Stanley Adjusts Price Target on Amgen

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.